purity testing is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-04. Numbers and descriptions here follow the published literature rather than marketing material.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
=== Preliminary actions === In January 2025, US President Donald Trump signed Executive Order 14157 that directed the US State Department to label certain Western Hemisphere drug cartels as Foreign Terrorist Organizations and Specially Designated Global Terrorists. In February, the Trump administration designated Tren de Aragua, a criminal organization from Venezuela; MS-13; and six Mexico-based groups as foreign terrorist organizations, saying at the time they posed "a national-security threat beyond that posed by traditional organized crime". In July, the US designated the Cartel of the Suns (Cartel de los Soles)—a criminal organization that the US alleges has ties to the Venezuelan leadership—as a Specially Designated Global Terrorist. At the time, the US State Department's Bureau of Western Hemisphere Affairs posted on X that it would use "all the resources at our disposal to prevent Maduro from continuing to profit from destroying American lives and destabilizing our hemisphere". US intelligence assessments have repeatedly contradicted claims made by the Trump administration in legal filings that Maduro controlled Tren de Aragua. The "terrorist organization" designation for Sinaloa Cartel, the Jalisco New Generation Cartel, Cártel del Noreste, Tren de Aragua, MS-13, the Gulf Cartel, and La Nueva Familia Michoacana Organization established the foundation for US intervention. In July, Trump secretly signed an executive order directing the armed forces to invoke military action against cartels that had been declared as terrorist organizations.
Ipglycermides are a class of non-natural macrocyclic peptide (MCP) inhibitors that target cofactor-independent phosphoglycerate mutases (iPGMs). The activity of human phosphoglycerate mutase requires the cofactor 2,3-bisphosphoglycerate (dPGM), whereas a structurally unrelated isozyme found in many parasitic species functions without a cofactor (iPGM). This variation in mechanism and evolutionary origin presents a potential drug target for selectively inhibiting glycolysis in pathogenic organisms. Specifically, they have shown promise in fighting filarial (round worm) diseases such as those caused by Brugia malayi, Onchocerca volvulus, and Dirofilaria immitis (heartworm). Ipglycermides are composed of 14 amino acids and contain an 8-membered macrocycle formed through a thioether bridge connecting the D-Tyr1 α-acetamide and Cys8 sulfhydryl side chain. Compared to most small-molecule drugs, there are more interactions with the drug target that allow them to work at significantly lower concentrations.
== Research == CPA has been studied and used in combination with low-dose diethylstilbestrol in the treatment of prostate cancer. The combination results in suppression of testosterone levels into the castrate range, which normally cannot be achieved with CPA alone. CPA has been studied as a form of androgen deprivation therapy for the treatment of benign prostatic hyperplasia (enlarged prostate). The medication has been studied in the treatment of breast cancer as well. CPA has been studied for use as a potential male hormonal contraceptive both alone and in combination with testosterone in men. CPA was under development by Barr Pharmaceuticals in the 2000s for the treatment of hot flashes in prostate cancer patients in the United States. It reached phase III clinical trials for this indication and had the tentative brand name CyPat but development was ultimately discontinued in 2008. CPA is not satisfactorily effective as topical antiandrogen, for instance in the treatment of acne. CPA has been used to treat estrogen hypersensitivity vulvovaginitis in women. CPA has been investigated for use in reducing aggression and self-injurious behavior via its antiandrogenic effects in conditions like autism spectrum disorders, dementias like Alzheimer's disease, and psychosis. CPA may be effective in the treatment of obsessive–compulsive disorder (OCD). CPA has been studied in the treatment of cluster headaches in men.
=== Diabetes-like symptoms === While sirolimus inhibition of mTORC1 appears to mediate the drug's benefits, it also inhibits mTORC2, which results in diabetes-like symptoms. This includes decreased glucose tolerance and insensitivity to insulin. Sirolimus treatment may additionally increase the risk of type 2 diabetes. In mouse studies, these symptoms can be avoided through the use of alternate dosing regimens or analogs such as everolimus or temsirolimus.
=== NASA Visualization Explorer === On July 26, 2011, NASA released the NASA Visualization Explorer app for the iPad. The application delivers real-time satellite data, including movies and stills, of Earth, that enable users to learn about subjects such as climate change, Earth's dynamic systems and plant life on land and in the oceans. The content is accompanied by short descriptions about the data and why it is important.
Sources: en.wikipedia.org
== Teams == For the 2019 season the following teams were not listed by the UCI at UCI Women's team level: Alasayl Cycling Team, Cylance Pro Cycling, Experza–Footlogix, S.C. Michela Fanini Rox, Storey Racing, UnitedHealthcare and Wiggle High5.
tracer A molecule or a specific atom within a molecule that has been chemically or radioactively labelled so that it can be easily tracked or followed through a biochemical process or located in a cell or tissue.
=== 1980s and 1990s === Pritzker first became involved in politics while an undergraduate student at Duke University, volunteering for Terry Sanford's 1986 campaign for the U.S. Senate. After graduating from Duke in 1987, Pritzker moved to Washington, D.C., to work on Capitol Hill. He served on the legislative staffs of Congressman Tom Lantos of California and Senator Alan J. Dixon of Illinois, focusing on trade and transportation issues. After his career as a staffer, Pritzker founded Democratic Leadership for the 21st Century, a national organization dedicated to attracting voters under 40 to the Democratic Party, in 1991. Anticipating that Sidney Yates, the longtime Democratic incumbent in Illinois's 9th congressional district, might retire instead of seeking reelection, Pritzker laid the groundwork for possible 1994 and 1996 campaigns for his seat. Each time, there was public speculation about whether Yates would retire, but he ultimately ran for reelection. Each time, after Yates announced his intention to run, Pritzker abandoned his plans to run. Pritzker established a campaign committee in 1993. By the end of the 1996 cycle, the committee had raised more than $120,000 and spent most of this money on operating expenditures.
Hydroxychloroquine, sold under the brand name Plaquenil among others, is a medication used to prevent and treat malaria in areas where malaria remains sensitive to chloroquine. Other uses include treatment of rheumatoid arthritis, lupus, and porphyria cutanea tarda. It is taken by mouth, often in the form of hydroxychloroquine sulfate. Common side effects may include vomiting, headache, blurred vision, and muscle weakness. Severe side effects may include allergic reactions, retinopathy, and irregular heart rate. Although all risk cannot be excluded, it remains a treatment for rheumatic disease during pregnancy. Hydroxychloroquine is in the antimalarial and 4-aminoquinoline families of medication. Hydroxychloroquine was approved for medical use in the United States in 1955. It is on the World Health Organization's List of Essential Medicines. In 2023, it was the 131st most commonly prescribed medication in the United States, with more than 4 million prescriptions. Hydroxychloroquine has been studied for an ability to prevent and treat coronavirus disease 2019 (COVID-19), but clinical trials found it ineffective for this purpose and a possible risk of dangerous side effects. Among studies that deemed hydroxychloroquine intake to cause harmful side effects, a publication by The Lancet was retracted due to data flaws. The speculative use of hydroxychloroquine for COVID-19 threatens its availability for people with established indications.
Sources: en.wikipedia.org
A 2018 systematic review and network meta-analysis of 50 trials involving 12 different psychosocial interventions for amphetamine, methamphetamine, or cocaine addiction found that combination therapy with both contingency management and community reinforcement approach had the highest efficacy (i.e., abstinence rate) and acceptability (i.e., lowest dropout rate). Other treatment modalities examined in the analysis included monotherapy with contingency management or community reinforcement approach, cognitive behavioral therapy, 12-step programs, non-contingent reward-based therapies, psychodynamic therapy, and other combination therapies involving these. As of December 2019, there is no effective pharmacotherapy for methamphetamine addiction. A systematic review and meta-analysis from 2019 assessed the efficacy of 17 different pharmacotherapies used in randomized controlled trials (RCTs) for amphetamine and methamphetamine addiction; it found only low-strength evidence that methylphenidate might reduce amphetamine or methamphetamine self-administration. There was low-to moderate-strength evidence of no benefit for most of the other medications used in RCTs, which included antidepressants (bupropion, mirtazapine, sertraline), antipsychotics (aripiprazole), anticonvulsants (topiramate, baclofen, gabapentin), naltrexone, varenicline, citicoline, ondansetron, prometa, riluzole, atomoxetine, dextroamphetamine, and modafinil. Medication-Assisted Treatment (MAT) combines FDA-approved medications with behavioral therapies to address substance use disorders.
The Strecker amino acid synthesis, also known simply as the Strecker synthesis, is a method for the synthesis of amino acids by the reaction of an aldehyde with cyanide in the presence of ammonia. The condensation reaction yields an α-aminonitrile, which is subsequently hydrolyzed to give the desired amino acid. The method is used for the commercial production of racemic methionine from methional.
. The mechanics of contacting rough surfaces are discussed in terms of normal contact mechanics and static frictional interactions. Natural and engineering surfaces typically exhibit roughness features, known as asperities, across a broad range of length scales down to the molecular level, with surface structures exhibiting self affinity, also known as surface fractality. It is recognized that the self affine structure of surfaces is the origin of the linear scaling of true contact area with applied pressure. Assuming a model of shearing welded contacts in tribological interactions, this ubiquitously observed linearity between contact area and pressure can also be considered the origin of the linearity of the relationship between static friction and applied normal force. In contact between a "random rough" surface and an elastic half-space, the true contact area is related to the normal force
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.